Four neonates suffered caval thrombosis secondary to indwelling central catheters. Dissolution of thrombus with recombinant tissue plasminogen activator (rt-PA) as a low-dose infusion (0.05 mg/kg/hr) directly into thrombus was successful in three patients. rt-PA was ceased after three days in the fourth patient because of catheter malposition. Thrombolysis was achieved between four and ten days. Rethrombosis occurred in one patient despite heparin prophylaxis. Plasminogen activator infusions were titrated to maintain fibrinogen levels above 100 mg/dl. One neonate suffered an intracranial haemorrhage. Regional rt-PA is an alternative to thrombectomy in critically ill neonates.
Low-dose infusions (0.02-0.1 mg/kg/hour) of recombinant tissue plasminogen activator (rt-PA) have been used for thrombolysis in peripheral arteries and bypass grafts in adults. 1·3 Recombinant tissue plasminogen activator has a short biological half-life, no antigenicity and in low doses induces only a minor plasma proteolytic state. 4 It therefore has potential advantages over other thrombolytic agents in critically ill newborn children.
We describe our experience using low dose regional infusions of rt-PA in four neonates with caval thrombosis.
MATERIALS AND METHODS
Over a twelve-month period we managed four sick neonates with caval thromboses using lowdose infusions of rt-PA. The rt-PA (Boehringer Ingelheim) was used on a case-by-case humanitarian salvage attempt basis. Informed parental consent was obtained for each patient.
Systemic fibrinolysis was contraindicated in these neonates -all had recent thoracotomies and central venous catheters, two were premature, and one had recent cardiopulmonary resuscitation. Local delivery of rt-PA (0.01-0.05 mglkg/hr) was elected the most practical method of clot lysis.
Central catheters remained in situ for local delivery. These were changed over guidewires in two cases to achieve both a better position and more effective delivery using a catheter with an end and side holes. Infusions of rt-PA were continued until objective evidence (ultrasound or venography) of lysis was achieved. Our technique involved the gradual withdrawal of catheters by 1 cm per day so as to maintain rt-PA infusions into thrombus. Vascular surgery remained an option in the event of failure of fibrinolysis.
To avoid the possibility of rethrombosis a heparin infusion (10 IU/kg/hr) was continued after rt-PA therapy. Activated partial thromboplastin times (APTT) were maintained 50% above normal.
Coagulation studiesprothrombin time, APTT, fibrinogen concentrations, fibrin degradation products (FDPs) and platelet countwere measured daily. Infusion rates of rt-PA were adjusted according to fibrinogen levels. We kept fibrinogen levels above 100 mg/dl. These were measured using the Clauss method. 5 Plasminogen levels were not measured.
All four neonates were monitored with cerebral ultrasound examinations performed twice weekly during fibrinolytic therapy. When clinically indicated a CT scan was performed.
PATIENT 1
This was a 33-week premature neonate who had pulmonary atresia. A pulmonary valvotomy and left subclavian to pulmonary artery (Blalock) shunt, done on day 2, was followed by a balloon septostomy via the right femoral vein on day 22. Anuria on day 25 heralded complete inferior cava (IYC) thrombosis, documented by Doppler ultrasound. An infusion of rt-PA (0.05 mglkglhr) was begun via the right femoral vein ( Figure 1 ). Urine output improved by day 29 and venography showed flow in both the right renal vein and the IYC above the renal veins. Infusion of rt-PA was reduced to 0.01 mglkglhr when fibrinogen levels decreased 50%. Heparin was given at 10 IU/kglhr from days 29 to 35. A venogram on day 33 showed free flow ( Figure 2 ). Cerebral ultrasounds on days 4, 10 and 20 were normal, but on day 33 ultrasound showed a I cm left posterior cerebral haemorrhage. Computerised axial tomography (CT) confirmed the parenchymal lesion and showed blood in the ventricular system. Cerebral ultrasound one month later showed resolving haematoma. A term child with trisomy 21 presented at one month of age for repair of an atrioventricular septal defect. Postoperative recovery was complicated by persistent heart failure due to mitral valve regurgitation. On day 12 postoperatively, increased chest wall oedema and pleural effusions heralded superior vena caval (SYC) obstruction. Plasminogen activator was infused through an indwelling 20 standard wire gauge (SWG) right internal jugular catheter from days 12 to 15. Heparin was then administered for a further twelve days. A repeat venogram showed patency of the SVC with no evidence of thrombus. Serial cerebral ultrasounds were normal. PATIENT 3 This term neonate was transferred to our unit at three weeks of age with severe lung disease complicated by recurrent pneumothoraces, sepsis and renal failure. At thoractomy, performed on day 24 for persistent air leaks, ruptured cysts in the apices of both lungs were oversewn. Venovenous haemofiltration via an 11.5Fr double lumen catheter inserted surgically into the right internal jugular vein was initiated to control gross oedema and renal failure. Haemofiltration was continued for five days. The catheter was removed because of methicillin-resistant staphylococcus aureus (MRSA) sepsis. This organism was grown from blood and catheter-tip cultures. Persistent thoracic oedema and pleural effusions heralded extensive thrombosis of SVC, innominate, subclavian and internal jugular veins on day 36.
A 20 SWG left subclavian line was introduced by a cutdown technique. This was advanced 0.5 cm before resistance was felt and an rt-PA infusion started. A venogram on day 40 (after four days of rt-PA) revealed good forward flow proximal to the catheter tip. Heparin was started and rt-PA stopped.
Suspicion of an obstructed IVC presenting as lower limb oedema was confirmed by ultrasound on day 40. A 20 SWG catheter had been in the left femoral vein for ten days. A new catheter was introduced over a guidewire to lie within the thrombus. Plasminogen activator was infused from day 40 to 50. A venogram confirmed successful lysis.
Despite a continued heparin infusion, a repeat venogram on day 65 demonstrated recurrence of thrombosis. Surgical exploration on day 66 revealed complete occlusion of all the central veins. Thrombectomy was performed without success. The child died on day 68.
Cerebral ultrasound investigations throughout treatment were normal. It is not known whether this child had a hypercoagulable state, however studies of protein C and antithrombin III were normal. PATIENT 
4
A 32-week gestation neonate had a ventricular septal defect (VSD), coarctation of the aorta and a patent ductus arteriosus (PDA) for which he underwent a subclavian flap coarctation repair, ductus arteriosus ligation and pulmonary artery banding at three weeks of age. Upper torso oedema developed on day 43. A venogram revealed SVC obstruction.
Plasminogen activator (0.05 mg/kg/hr) was started through an indwelling 22 SWG double lumen catheter. Gradual withdrawal of the catheter on day 46 resulted in the proximal lumen extravasating into the skin. The catheter was removed completely and heparin started through a peripheral line. A venogram showed no filling of the SVc.
A thoracotomy was performed on day 46. A thrombectomy was performed on the SVC and innominate veins with good result. Warfarin was introduced and once therapeutic levels were achieved, heparin was stopped.
Despite these measures chest wall oedema reaccumulated within a few weeks. A further venogram revealed rethrombosis of the SVC and left innominate veins.
The child remained ventilator dependent. A bronchogram showed hypoplastic main bronchi. The child died on day 100.
RESULTS
Basic data and results are shown in Table 1 . Thrombus lysis was successful in two patients who survived and one who succumbed due to rethrombosis (patient 3). This occurred despite heparinisation. Treatment failed in the fourth patient. Plasminogen activator was ceased after three days because of catheter malposition. Thrombectomies were performed on patients 3 and 4 without success.
Successful lysis was achieved in the SVC after four days in patients 2 and 3, while the IVC thromboses required nine to ten days in patients 1 and 4. Catheter withdrawal was made in response to successful lysis about the catheter tip. This was monitored daily by ultrasound or venography, so the rate of withdrawal was dictated by monitoring availability.
Fibrinogen levels in patients 1, reflecting the degree of systemic fibrinolysis, are shown graphically in Figure 3 . The sensitivity of fibrinogen levels to infusion rate is shown. After 24 hours ofrt-PA of 0.05 mg/kg/hr, plasma fibrinogen fell to 136 mg/dl. Withholding rt-PA for four hours saw a rise in levels to 229 mg/dl. After five days of rt-PA, venography showed the cathether tip to be above the thrombus margin. Fibrinogen dropped from 240 mg/dl to 124 mg/dl. FDPs rose from 4 to 16 mg/dl (N < 0.2 mg/dl). The infusion rate was lowered to 0.01 mg/kg/hr, and the catheter withdrawn back into the thrombus. Fibrinogen levels rose and FDPs fell to 2 mg/dl. Risius et al,2 note that the Clauss method of fibrinogen determination gives lower levels of measured fibrinogen than other methods because of interference by FDPs with this assay. The value of 124 mgldl recorded in patient 1 may be a falsely low reading.
DISCUSSION
Tissue plasminogen activator is a thrombolytic agent with a high rate ratio of activity for fibrinbound plasminogen. Selective thrombolysis with sparing of plasma fibrinogen when rt-PA is administered systematically does not occur. A lytic state can be produced. 6 Haemorrhagic complications are similar to those of streptokinase due to disruption of haemostatic plugs. It was our hope that local delivery of rt-PA avoided systemic fibrinolysis. The falling fibrinogen in the reported patients indicates that regional infusion failed to remain localised. This is seen in patient 1. Fibrinogen levels dropped 50% when the infusion catheter protruded beyond the thrombus margin.
Dosage regimen between patients differed. Doses were titrated to both fibrinogen levels and objective evidence of thrombolysis from ultrasound or venography. Marder and Sherry claim there is no relation between angiographic improvement and the degree of abnormality in laboratory results.? We maintained fibrinogen Abbreviations: A YC = atrioventricular canal; BAS = balloon artrial septostomy; PDA = patient ductus arteriosus; YSD = ventricular septal defect; IYH = intraventricular haemorrhage levels above 100 mg/dl in order to mInImISe haemorrhagic events. Despite keeping fibrinogen levels above 100 mg/dl, patient I suffered an intracerebral bleed. Our experience with using rt-PA for caval thrombolysis is limited. If the risk of intracranial haemorrhage is as high as 25%, this may well be unacceptable. We attribute this haemorrhage to thrombolytic therapy. The chance that a 33-week premature neonate with normal coagulation will have a spontaneous intracranial haemorrhage on day 33 is extremely low. The risk of serious bleeding complications during adult thrombolytic therapy is about 5%. 4 Marder and Sherry report poor correlation between the extent of hypofibrinogenaemia and haemorrhagic events. They suggest vascular injury rather than changes in blood coagulation is the main cause of bleeding. Patient I did not have bleeding from venepuncture or surgical sites even when fibrinogen levels decreased 50%.
Thrombolysis of clots occurred over many days. The gradual dissolution of clot related to catheter site, and in one patient the rethrombosis, which occurred after ceasing rt-PA, suggests lysis was due to rt-P A infusion rather than spontaneos lysis. This confirms animal work on clot lysis done by Collen et al. 8 They noted local delivery of the agent to be important for thrombolysis. Collateral flow and subsequent dilution of the drug limit its effectiveness.
Clot age has an influence on its susceptibility to lysis. Although Collen et al. 8 noted the age of the clot (up to seven days) had little influence on its susceptibility to lysis, most in vivo studies suggest clots become more resistant to lysis as they age, 7 partly because of alpha-chain crosslinking of the fibrin monomers. The sooner therapy is started, the better the outcome. Thrombinolysis failed in one of our patients. Therapy was initiated early. We believe catheter malposition was responsible for failure. Re-perfusion failure does occur in adult therapy. The experience in the arterial and venous circulations are not necessarily comparable. Treatment of neonatal caval thrombosis is probably comparable to adult deep vein thrombosis and pulmonary embolism. Thrombolytic therapy is more successful with these patients than in those with coronary or arterial thrombosis where atheromatous disease is more prevalent. . -Rethrombosis occurred in one patient. A thrombolytic agent with an extended half-life may decrease the incidence of rethrombosis in coronary artery thrombolysis. The short half-life of rt-PA may leave an underlying vessel lesion exposed resulting in rethrombosis. 7 This argument does not apply after an infusion of at least four days in our patients compared to four hours in those undergoing coronary thrombolysis. Rethrombosis occurred in patient 3 despite a heparin infusion. Investigation of clotting factors was normal. Heparin may induce platelet aggregation. 9 The use of heparin and aspirin has not markedly reduced rates of re-occlusion after coronary thrombolysis. 10 Undissolved thrombus, re-exposure of collagen on vessel walls, or platelet activation may all contribute to rethrombosis. Patient 3 may have had an underlying septic thrombophlebitis which contributed to rethrombosis.
Recombinant tissue plasminogen activator was chosen ahead of other agents for our patients in the hope that this agent had less systemic activation of plasminogen, fewer bleeding complications, and would result in quicker lysis time. Evidence for rt-PA superiority in the treatment of myocardial infarction is accumulating. This is not true of peripheral arterial occlusions. I I Bleeding complications and successful lysis at 24 hours are similar for different thrombolytic agents. Shortterm improvement in patients with pulmonary embolism are similar for streptokinase, urokinase and rt-PA. Sustained improvement with these agents when compared with heparin alone is not proven. Rethrombosis in coronary artery disease is 20% for rt-PA compared with 15% for streptokinase and 10% for urokinase. 7 Rethrombosis of veins is often secondary to incomplete lysis of the original thrombus. Local delivery, which is dependent on high local concentrations oflytic agent, may leave thrombosis on vessel walls as the catheter is withdrawn. Agents such as streptokinase, urokinase or acylated plasminogen-streptokinase activator complex, with their longer half-lives, may have advantages over rt-PA. There are few data available on use of these agents in neonatal caval thrombosis.
In conclusion, we believe regional infusion of rt-PA to be an alternative to thrombectomy in critically ill neonates. The method is effective, but the dose must be carefully monitored to avoid systemic fibronolysis.
